Ferrous Patents (Class 424/648)
  • Publication number: 20110183009
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: April 5, 2011
    Publication date: July 28, 2011
    Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventor: Eric Konofal
  • Patent number: 7964205
    Abstract: Bait compositions of spinosyns in combination with metal complexones and other mollusicides are provided in an environmentally safe composition that is effective to a treat and/or control a wide spectrum of insect and mollusc pests.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: June 21, 2011
    Assignee: W. Neudorff GmbH KG
    Inventors: Diana L. Parker, Cameron D. Wilson, George S. Puritch, David S. Almond
  • Patent number: 7935366
    Abstract: A new prophylactic mixture is prepared for the effective decorporation of *Cs, *Sr, *I from affected subjects in the event of an accidental release of the radioisotopes in the environment due to any nuclear accident. The prophylactic mixture comprising: 1) Calcium Potassium Ferrocyanide [CaK2Fe(CN)6] 2) Calcium Iodate, and 3) Calcium Carbonate, can be formulated in the form of a single tablet, capsule or suspension for easy administration to the radiation affected subjects in cases of emergency or nuclear fallout. Also claimed are the compound calcium potassium ferrocyanide (CaK2Fe(CN)6) and the use thereof for decorporation of *Cs in subjects affected by nuclear radiation.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: May 3, 2011
    Assignee: Secretary, Department of Atomic Energy
    Inventors: Dharampal Nandiram Pahuja, Vikram Sarjerao Jagtap, Vinay Ramkrishna Sonawane
  • Patent number: 7931910
    Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: April 26, 2011
    Assignee: W. Neudorff GmbH KG
    Inventor: Diana L. Parker
  • Publication number: 20110052722
    Abstract: The invention relates to compositions and methods for the treatment or prophylaxis of iron deficiency, and in particular of iron deficiency anemia, by administering a composition containing an effective amount of a pharmaceutically acceptable ferrous iron salt; and an effective amount of polysaccharide iron complex.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 3, 2011
    Applicant: Grace Procurements LLC
    Inventors: Peter J. Krebs, Allison Krebs-Bensch, Jerome W. Mincy
  • Publication number: 20110020270
    Abstract: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
    Type: Application
    Filed: December 9, 2008
    Publication date: January 27, 2011
    Inventors: Jean-Pierre Levesque, Ingrid Winkler
  • Publication number: 20110002881
    Abstract: This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
    Type: Application
    Filed: November 7, 2008
    Publication date: January 6, 2011
    Applicant: Mater Medical Research Institute
    Inventors: Jean-Pierre Levesque, Ingrid Winkler
  • Publication number: 20100330199
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Application
    Filed: January 12, 2009
    Publication date: December 30, 2010
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • Publication number: 20100317519
    Abstract: Mixtures are described comprising two or more compounds selected from at least two of the following groups: i) salicylic acid and/or its functional analogous products (ESA), ii) promoting compounds (PRO) and iii) modulating compounds (MOD), and their use for stimulating the natural defence systems of plants and for inducing resistance in plants. The use is also described, of two or more compounds selected from at least two of the following groups: one or more compounds belonging to the ESA group and/or one or more compounds belonging to the PRO group and/or one or more compounds belonging to the MOD group, individually adopted by means of application programs which envisage alternating application, to stimulate the natural defence systems of plants and inducing resistance in plants.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 16, 2010
    Applicant: ISAGRO S.P.A.
    Inventors: LUCIO FILPPINI, MARILENA GUSMEROLI, SILVIA MORMILE, CARLO GARAVAGLIA, LUIGI MIRENNA
  • Publication number: 20100303928
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
    Type: Application
    Filed: December 2, 2008
    Publication date: December 2, 2010
    Applicant: FibroGen, Inc.
    Inventors: Michael P. Arend, Heng Cheng, Lee A. Flippin, Danny Ng, Eric D. Turtle, Min Wu
  • Publication number: 20100266647
    Abstract: Compositions comprising a gel system made from a combination of a fractal network of nanoparticles and translucent macroscopic particles, titanium dioxide and other color pigments is disclosed. The compositions are capable of forming an effective film on the biological surface such as skin to blurring fine lines and wrinkles while retaining a natural look of the skin as a consequence of synergy between the fractal particles, the macroscopic particles, titanium dioxide and color pigments. Also disclosed methods for their use.
    Type: Application
    Filed: November 14, 2008
    Publication date: October 21, 2010
    Applicant: AVON PRODUCTS, INC.
    Inventors: Ajay G. Dingley, Michael J. Fair, John R. Glynn, JR., Giovana A. Sandstrom
  • Publication number: 20100233245
    Abstract: The present invention relates to nanoparticle composition comprising cellulose nanofibers embedded with nanosized material. More particularly the present invention relates to cellulose nanofibers embedded with silver or iron oxide embedded silver. In addition the present invention is also related to the preparation of the cellulose nanofibers embedded with nanosized material. The nanoparticle composition is antibacterial in nature and can be utilized in various antibacterial applications.
    Type: Application
    Filed: November 14, 2008
    Publication date: September 16, 2010
    Applicant: Jawaharlal Nehru Centre for Advanced Scientific Research
    Inventor: Chandrabhas Narayana
  • Publication number: 20100172916
    Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: November 9, 2009
    Publication date: July 8, 2010
    Applicant: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
  • Publication number: 20100150898
    Abstract: Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.
    Type: Application
    Filed: February 22, 2010
    Publication date: June 17, 2010
    Inventor: Richard C. Boucher, Jr.
  • Publication number: 20100135950
    Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.
    Type: Application
    Filed: June 25, 2007
    Publication date: June 3, 2010
    Applicant: Genzyme Corporation
    Inventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
  • Publication number: 20100098677
    Abstract: Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.
    Type: Application
    Filed: December 21, 2009
    Publication date: April 22, 2010
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Richard Rox Anderson, Bernhard Ortel, Eliot F. Battle, Edwin K. Joe
  • Publication number: 20100047367
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
    Type: Application
    Filed: August 20, 2009
    Publication date: February 25, 2010
    Inventors: Shaojiang Deng, Wen-Bin Ho, Lee A. Flippin
  • Publication number: 20090317488
    Abstract: A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations.
    Type: Application
    Filed: September 27, 2007
    Publication date: December 24, 2009
    Applicant: Tris Pharma, Inc
    Inventors: Ketan Mehta, Yu-Hsing Tu, Mahendra Shah
  • Publication number: 20090304816
    Abstract: A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier.
    Type: Application
    Filed: December 6, 2006
    Publication date: December 10, 2009
    Applicant: CEREUSCIENCE AB
    Inventors: Ludger Grote, Jan Hedner, Kaj Stenlof
  • Publication number: 20090297628
    Abstract: Use of a stone extract as stimulant of the synthesis of collagen by skin fibroblasts.
    Type: Application
    Filed: September 22, 2006
    Publication date: December 3, 2009
    Applicant: GATTEFOSSE SAS
    Inventors: Nathalie Launay, Ghislaine Passaro, Frederic DeMarne
  • Publication number: 20090280191
    Abstract: The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present.
    Type: Application
    Filed: June 29, 2006
    Publication date: November 12, 2009
    Applicant: J-PHARMA CO., LTD.
    Inventors: Hitoshi Endou, Tomotaka Yanagita, Koji Yamashita
  • Publication number: 20090246254
    Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 1, 2009
    Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
  • Patent number: 7578997
    Abstract: This invention relates to high surface area materials, such as nanoparticles, that are coated with metal ions. These modified nanoparticles have active sites that bind various gases and/or odorous compounds, thereby removing these compounds from a medium such as air or water. Metal ions are adsorbed onto the surface of the nanoparticle and bound strongly to the surface. By selection of the metal ion, specific gaseous compounds and/or odorous compounds can be targeted and removed efficiently and effectively from both aqueous phase and from the air. The modified nanoparticles are useful in numerous article of manufacture for industrial and consumer use.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: August 25, 2009
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventor: John Gavin MacDonald
  • Patent number: 7560123
    Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: July 14, 2009
    Assignee: Everett Laboratories, Inc.
    Inventors: John A. Giordano, Charles J. Balzer
  • Patent number: 7553479
    Abstract: Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: June 30, 2009
    Assignee: AMAG Pharmaceuticals, Inc.
    Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
  • Publication number: 20090136594
    Abstract: The present invention includes compositions, methods, devices and kits for magnetizing a biological particle by contacting a biological particle with a ferrous or magnetic particle that is able to specifically bind the biological particle and reacting the biological particle with the ferrous or magnetic particle under physiological conditions, wherein the ferrous or magnetic particle causes the biological particle to become attractable magnetically.
    Type: Application
    Filed: November 26, 2008
    Publication date: May 28, 2009
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Stacey L. McLeroy, Bruce E. Gnade, Jeffrey A. Cadeddu, Margaret Pearle
  • Publication number: 20090117168
    Abstract: An implantable device for attracting diseased cells or foreign substances circulating within bodily fluid channels is disclosed. The device comprises a frame, an attachment means for maintaining the frame in a localized position in a body vessel, and at least one attractant on the frame, where the attractant is capable of attracting a diseased cell or a foreign substance. The device may also include a therapeutic agent The device may be used for diagnosis, disease containment or treatment. The device may also be used for attracting and localized treatment of diseased cells and foreign substances.
    Type: Application
    Filed: November 9, 2004
    Publication date: May 7, 2009
    Applicant: H.E.F.
    Inventor: James Keenan
  • Publication number: 20090041858
    Abstract: The present invention is the development of haemostatic compositions that use nitrogen containing organic polymers in combination with haemostatic agents to create a gel form. Compositions utilizing the polymers exhibit relatively lower concentrations of haemostatic agents, drawing benefits from such lower concentrations as they limit unwanted side effects of the haemostatic agents. Preferred compositions utilize Poly(N-vinylpyrrolidone), Poly(2-ethyl-2-oxazoline) as thickening agents and ferric sulfate as an active ingredient.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 12, 2009
    Applicant: CAO GROUP, INC.
    Inventor: Steven D. Jensen
  • Publication number: 20090035385
    Abstract: Compositions and methods for prevent, stabilize, reverse or treat disorders related to iron deficiency in a human or other animal. In a first embodiment, the composition includes about 10 mg to about 500 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; and about 5 mg to about 500 mg of one or more forms of an organic acid. In another embodiment, the composition includes about 50 to about 150 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; about 50 to about 250 mg of one or more forms of an organic acid; about 150 to about 250 mg of one or more forms of ascorbic acid; about 0.5 mg to about 1.5 mg vitamin B12; about 50 to about 150 mg intrinsic factor; and about 0.5 mg to about 1.5 mg folic acid.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 5, 2009
    Applicant: DRUGTECH CORPORATION
    Inventor: Jonathan David Bortz
  • Patent number: 7445799
    Abstract: An antimicrobial and chemical deactivating composition for use in a liquid medium or for incorporation into a coating, structural plastic materials, thin microporous membranes, textiles and sponges. The composition includes macrosize or submicron particles of silver, platinum with silver and their salts with parabens, oxide, salicylate, acetate, citrate, benzoate and phosphate along with copper and zinc salts of the same.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: November 4, 2008
    Assignee: ICET, Inc.
    Inventors: Shantha Sarangapani, Quoc T. Truong
  • Publication number: 20080213345
    Abstract: The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal.
    Type: Application
    Filed: September 13, 2005
    Publication date: September 4, 2008
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ning Hu, Gerard M. Jensen, Craig Skenes, Stephanie Yang
  • Patent number: 7407673
    Abstract: The present invention relates to radioactive magnetic fluids, process for preparing them and use thereof. Particularly, the present invention relates to the radioactive magnetic fluids for treatment or diagnosis of cancer, process for preparing them and use thereof. The radioactive magnetic fluids of the present invention include the component of Cu2+ which radiates a ?-ray and ?-ray. The ? radiation can effectively kill the tumor cells. Since the ? radiation are easily imaged with ?-camera, the magnetic fluids can be gathered to the treatment site with the radiograph under external magnetic field. Therefore, the radioactive magnetic fluids of the present invention can be used for treatment of cancer with minimal side effects. Also, the tightly bonded decanoic acid and nonanoic acid layer of the present invention not only increase particle-particle repulsion but also take hydrophilicity, to disperse homogeneously and stably the magnetic nanoparticles in water.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: August 5, 2008
    Inventors: Chong-Oh Kim, Jong-Hee Kim, Yuqiang Huang, Sang-Im Park
  • Patent number: 7393521
    Abstract: Composition and method for promoting growth of microbes that are capable of degrading animal waste. The method includes applying a nontoxic composition to a bedding substrate that is disposed to receive animal waste. The composition comprises a carboxylic acid, preferably the carboxylic acid is a fatty acid, and more preferably a combination of a saturated fatty acid and an unsaturated fatty acids. Specifically, a preferred composition comprises a saturated fatty acid having from 12 to 22 carbon atoms and an unsaturated fatty acid having from 12 to 22 carbon atoms. A still more preferred composition used both saturated and unsaturated fatty acids having from 16 to 20 carbon atoms. Optionally, the composition may include or encapsulate nutrients, an oxygen-releasing compound, or microbes.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: July 1, 2008
    Assignee: Bionutratech, Inc.
    Inventor: Sandra Hruza
  • Patent number: 7387799
    Abstract: The present invention relates to an anti-bacterial, anti-viral, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: June 17, 2008
    Assignee: Well-Being Biochemical Corp.
    Inventors: Jih-Ru Hwu, Shwu-Chen Tsay
  • Patent number: 7375139
    Abstract: A transdermal patch for the treatment of iron deficiency including a drug reservoir layer containing an hematinic substance; a rate-controlling membrane secured to said reservoir layer; and a contact adhesive secured to said rate-controlling membrane, wherein said hematinic substance is selected from the class consisting of ferrous sulfate, ferrous lactate, ferrous iodide, ferrous gluconate, ferrous fumarate, ferrous citrate, ferrous carbonate saccharated, ferrous carbonate mass, ferronascin, ferroglycine sulfate, and ferrocholinate.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: May 20, 2008
    Inventor: Katherine M. Aldred
  • Patent number: 7320804
    Abstract: The present invention relates to a cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough. The cough depressant composition of the present invention comprises 0.01-100% by weight of Fe2+(ferrous) or Fe3+(ferric). Furthermore, the cough depressant composition of the present invention can comprise an angiotensin-converting enzyme inhibitor. The cough depressant composition of the present invention relieves the pain of the patient by reducing continuous dry cough.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: January 22, 2008
    Assignee: Samsung Life Public Welfare Foundation Samsund Medical Center
    Inventors: Kyung-Pyo Hong, Seung-Woo Park, Sang-Chol Lee
  • Patent number: 7285292
    Abstract: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium and which comprises a concentration of the metal(s) of at least 60 mg/ml. The solution further comprises at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide. The trace element solution is prepared by a method consisting essentially of the steps of preparing a MnCO3 mixture in a container; adding an EDTA/NaOH mixture to the container and subsequently adding at least one metal compound; and adding Na2SeO3 to the container to obtain the trace element solution. The method also comprises the step of adding CrCl3.6H2O to the trace element solution.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: October 23, 2007
    Assignee: Warburton Technology Limited
    Inventors: Robert Naylor Laurie, William Alfred Smith
  • Patent number: 7135196
    Abstract: Compositions in solid form, such as powders, comprising a mixture of a ferrous salt and a hydroxypyrone maybe used to increase the level of iron in a patient's bloodstream or to treat and/or prevent gastrointestinal infection.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: November 14, 2006
    Assignee: Vitra Pharmaceuticals Limited
    Inventor: Michael Arthur Stockham
  • Patent number: 7022734
    Abstract: The use of transition metal complexes in the treatment of septic shock, in particular the hypotension associated therewith and pharmaceutical formulations comprising such complexes are disclosed. The use of such transition metal complexes in the treatment of other conditions caused by pathological NO production are also disclosed.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: April 4, 2006
    Assignee: Molichem Medicines, Inc.
    Inventors: Wieslaw Mieczyslaw Kazmierski, Luis Molina
  • Patent number: 6979466
    Abstract: The invention relates to nanoscale particles suited especially for use in tumor therapy by hyperthermia. Said particles comprise a (preferably superparamagnetic) iron oxide-containing core and at least two shells surrounding said core. The (innermost) shell adjoining the core is an envelope which comprises groups capable of forming cationic groups and is broken down by human or animal tissue at such a slow rate as to allow for association of the core surrounded by said envelope with the surface of cells and/or for absorption of said core into the inside of cells.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: December 27, 2005
    Assignee: Leibniz-Institut fuer neue Materialien Gemeinnuetzige GmbH
    Inventors: Christoph Lesniak, Thomas Schiestel, Helmut Schmidt, Andreas Jordan
  • Patent number: 6896909
    Abstract: The invention relates to formulations for the topical treatment of disorders with a bioenergetic basis, which contain a suspension obtainable by treating one or more iron ores with aqueous solutions having pH values of between 4 and 8. These formulations will be applied directly to the acupuncture points corresponding to the meridians involved in the conditions to be treated.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: May 24, 2005
    Assignee: GeoMedical S.r.l.
    Inventor: Mauro Fanelli
  • Patent number: 6893658
    Abstract: An object of the present invention is to provide soft capsule formulations of active vitamins D, well-suited to practical production with easy discrimination of active ingredient levels, in which stability of the active vitamins D3 to light and heat is ensured, and which material is highly safe to the human body. According to the present invention, soft capsule formulations of active vitamins D3 can be obtained-wherein the capsule shell contains a white pigment and yellow iron oxide and/or red iron oxide, or titanium oxide and caramel, or yellow iron oxide.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: May 17, 2005
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshimitsu Iida, Yutaka Ogawa
  • Patent number: 6852329
    Abstract: An effective, readily ingested molluscicidal bait poison includes a mollusc bait and a second component. The second component can contain a transition metal compound and a complexing agent, and/or the complex of a transition metal compound and a complexing agent. The complexing agent is preferably iminodisuccinic acid (IDS), including sodium IDS (IDS Na-Salt), iminodifumaric acid (IDF), iminoditartaric acid (IDT), iminodimaleic acid (IDMAL), ethylenediaminedifumaric acid (EDDF), ethylenediaminedimalic acid (EDDM), iminodimalic acid (IDM), ethylenediamineditartaric acid (EDDT), ethylenediaminedimaleic acid (EDDMAL), and salts thereof.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: February 8, 2005
    Assignee: W. Neudorff GmbH KG
    Inventors: George S. Puritch, Andreas Prokop, David S. Almond, Robert Matson
  • Patent number: 6841172
    Abstract: The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: January 11, 2005
    Assignee: HemoCleanse, Inc.
    Inventor: Stephen R. Ash
  • Patent number: 6818228
    Abstract: A vitamin and mineral supplement containing ULTRADENSE™ calcium citrate and carbonyl iron for use in humans. Calcium in the form of citrate enhances absorption of iron, zinc, and magnesium. ULTRADENSE™ calcium citrate provides more bioavailable calcium than usual preparations of calcium citrate. Carbonyl iron provides iron in a form that significantly reduces the risk to children of accidental iron poisoning from formulations that provide iron in salt form. The supplement may further contain a number of vitamins and minerals in a tablet that is elegantly small, weighing about 1.5-1.6 g. The small size allows ease of swallowing and encourages patient acceptability. Methods of making such a supplement and methods of treating maladies in need of vitamin and mineral supplementation are provided.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: November 16, 2004
    Assignee: Mission Pharmacal Company
    Inventors: Neill B. Walsdorf, Cindy L. Wabner, George Alexandrides
  • Publication number: 20040146584
    Abstract: This invention relates to a novel porous, sulpha sponge iron compound derived from haematite having the following composition given below: and having trace elements such as Au, Pt and Ag therein,by dissolving said haematite in concentrated hydrochloric acid. The acidic solution is treated with alcoholic ammonia and glacial acetic acid. The sulpha sponge iron compound has Fe2/Fe3 cores forming interstatially stabilized clusters. The invention also includes a process for desulphurising natural gas by adsorbing sulphur containing contaminants in the novel sulpha sponge iron compound either at the drilling site or on a bed containing the same.
    Type: Application
    Filed: December 5, 2003
    Publication date: July 29, 2004
    Inventor: Nadathur Venkata Ragahavan Therani
  • Patent number: 6767558
    Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceutical excipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceutical excipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: July 27, 2004
    Assignee: Pfizer Inc.
    Inventor: Hai Wang
  • Patent number: 6753016
    Abstract: A method for the protection of wood and other wood materials without affecting dimensional stability or surface integrity of the treated material is described. The method involves treating wood material with an iron salt and selected oxidants where the iron salt is preferably complexed with organic chelating ligands. Preferably, a microbicidal agent is also incorporated into the method to provide treated wood products that demonstrate excellent surface integrity, dimensional stability and retention of the infused microbicidal agents for extended periods of time without incurring the detrimental environmental effects of conventional chromium or copper-based inorganic salt preservation methods.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: June 22, 2004
    Assignee: Rohm and Haas Company
    Inventor: Tirthankar Ghosh
  • Patent number: 6703036
    Abstract: A stomach-action molluscicide, which includes a metal complexone and a suitable additive for enhancing the molluscicidal activity of the metal complexone. The additive may be selected from a surfactant or an additional source of ferric ions. Examples of the surfactant include sodium dodecyl sulphate or sorbitan monostearate, while an example of the additional source of ferric ions is ferric orthophosphate.
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: March 9, 2004
    Inventor: Colin Leslie Young
  • Patent number: 6696584
    Abstract: Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: February 24, 2004
    Assignee: Natural ASA
    Inventors: Daria Jerome, Carl Skarie